Immunovia AB (Publ) presents Nomination Committee
Immunovia AB (IMMNOV: Nasdaq Stockholm) has announced its Nomination Committee appointments ahead of the 2025 Annual General Meeting. The committee comprises four members representing 5.65% of shares and votes: Christer Køhler (representing Jens Henrik Jensen), Mats Leifland (representing Vincent Saldell), Sara Ek (representing Carl Borrebaeck), and Peter Høngaard Andersen as Board Chair.
CEO Jeff Borcherding declined to appoint a representative to ensure committee independence. The committee will prepare proposals for the AGM scheduled for May 14, 2025, including board nominations and compensation recommendations. The focus is on ensuring board competencies align with the company's transition from R&D to US commercialization.
Immunovia focuses on developing blood-based testing for early pancreatic cancer detection, targeting the US market where an estimated 1.8 million high-risk individuals could benefit from annual surveillance testing.
Immunovia AB (IMMNOV: Nasdaq Stockholm) ha annunciato le nomine del suo Comitato di Nomina in preparazione dell'Assemblea Generale Annuale 2025. Il comitato è composto da quattro membri che rappresentano il 5,65% delle azioni e dei voti: Christer Køhler (rappresentante di Jens Henrik Jensen), Mats Leifland (rappresentante di Vincent Saldell), Sara Ek (rappresentante di Carl Borrebaeck) e Peter Høngaard Andersen in qualità di Presidente del Consiglio.
Il CEO Jeff Borcherding ha rifiutato di nominare un rappresentante per garantire l'indipendenza del comitato. Il comitato si occuperà di preparare proposte per l'AGM programmata per il 14 maggio 2025, comprese le nomine al consiglio e le raccomandazioni relative al compenso. L'obiettivo è garantire che le competenze del consiglio siano in linea con la transizione dell'azienda dalla ricerca e sviluppo alla commercializzazione negli Stati Uniti.
Immunovia si concentra sullo sviluppo di test ematici per la rilevazione precoce del cancro pancreatico, mirando al mercato statunitense dove si stima che 1,8 milioni di individui ad alto rischio potrebbero beneficiare di un test di sorveglianza annuale.
Immunovia AB (IMMNOV: Nasdaq Estocolmo) ha anunciado sus nombramientos del Comité de Nominación de cara a la Junta General Anual 2025. El comité está compuesto por cuatro miembros que representan el 5,65% de las acciones y los votos: Christer Køhler (representando a Jens Henrik Jensen), Mats Leifland (representando a Vincent Saldell), Sara Ek (representando a Carl Borrebaeck) y Peter Høngaard Andersen como Presidente de la Junta.
El CEO Jeff Borcherding decidió no nombrar un representante para asegurar la independencia del comité. El comité se encargará de preparar propuestas para la AGM programada para el 14 de mayo de 2025, incluyendo nominaciones para la junta y recomendaciones de compensación. El enfoque es asegurar que las competencias de la junta se alineen con la transición de la empresa de I+D a la comercialización en EE.UU.
Immunovia se centra en desarrollar pruebas basadas en sangre para la detección temprana del cáncer pancreático, apuntando al mercado estadounidense donde se estima que 1,8 millones de individuos de alto riesgo podrían beneficiarse de pruebas de vigilancia anuales.
Immunovia AB (IMMNOV: 나스닥 스톡홀름)은 2025년 정기 주총을 앞두고 후보추천위원회 임명을 발표했습니다. 위원회는 5.65%의 주식과 투표를 대표하는 네 명의 위원으로 구성되어 있습니다: Christer Køhler (Jens Henrik Jensen을 대표), Mats Leifland (Vincent Saldell을 대표), Sara Ek (Carl Borrebaeck을 대표) 및 Peter Høngaard Andersen (이사회 의장).
CEO Jeff Borcherding은 위원회의 독립성을 보장하기 위해 대표를 임명하지 않기로 결정했습니다. 위원회는 2025년 5월 14일로 예정된 정기 주총을 위한 제안서를 준비할 것입니다. 여기에는 이사회 후보 및 보상 추천이 포함됩니다. 또한 이사회의 역량이 회사의 연구개발에서 미국 상업화로의 전환에 부합하도록 하는 것이 초점입니다.
Immunovia는 조기 췌장암 검출을 위한 혈액 기반 테스트 개발에 집중하고 있으며, 미국 시장을 목표로 하고 있습니다. 여기서는 약 180만 명의 고위험 개인이 연간 검진 테스트의 혜택을 받을 수 있을 것으로 추정됩니다.
Immunovia AB (IMMNOV: Nasdaq Stockholm) a annoncé les nominations de son Comité de Nomination en vue de l'Assemblée Générale Annuelle de 2025. Le comité est composé de quatre membres représentant 5,65 % des actions et des votes : Christer Køhler (représentant Jens Henrik Jensen), Mats Leifland (représentant Vincent Saldell), Sara Ek (représentant Carl Borrebaeck) et Peter Høngaard Andersen en tant que Président du Conseil.
Le CEO Jeff Borcherding a refusé de nommer un représentant afin d'assurer l'indépendance du comité. Le comité préparera des propositions pour l'AGM prévue le 14 mai 2025, y compris des nominations au conseil et des recommandations de compensation. L'accent est mis sur l'assurance que les compétences du conseil correspondent à la transition de la société de la R&D vers la commercialisation aux États-Unis.
Immunovia se concentre sur le développement de tests sanguins pour la détection précoce du cancer du pancréas, visant le marché américain où environ 1,8 million de personnes à haut risque pourraient bénéficier de tests de surveillance annuels.
Immunovia AB (IMMNOV: Nasdaq Stockholm) hat die Ernennungen ihres Nominierungsausschusses im Vorfeld der Hauptversammlung 2025 bekannt gegeben. Der Ausschuss besteht aus vier Mitgliedern, die 5,65% der Aktien und Stimmen vertreten: Christer Køhler (im Namen von Jens Henrik Jensen), Mats Leifland (im Namen von Vincent Saldell), Sara Ek (im Namen von Carl Borrebaeck) und Peter Høngaard Andersen als Vorsitzender des Vorstands.
CEO Jeff Borcherding hat abgelehnt, einen Vertreter zu ernennen, um die Unabhängigkeit des Ausschusses zu gewährleisten. Der Ausschuss wird Vorschläge für die Hauptversammlung am 14. Mai 2025 vorbereiten, einschließlich der Vorschläge für die Zusammensetzung des Vorstands und Empfehlungen zur Vergütung. Der Fokus liegt darauf, sicherzustellen, dass die Kompetenzen des Vorstands mit dem Übergang des Unternehmens von Forschung und Entwicklung zur Vermarktung in den USA übereinstimmen.
Immunovia konzentriert sich auf die Entwicklung blutbasierter Tests zur frühzeitigen Erkennung von Bauchspeicheldrüsenkrebs, mit dem Ziel des US-Marktes, wo schätzungsweise 1,8 Millionen Hochrisikopersonen von jährlichen Überwachungstests profitieren könnten.
- Company transitioning from R&D to commercialization phase in the US market
- Large addressable market with 1.8 million high-risk individuals in the USA
- None.
According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which three should be appointed by the Company's three largest shareholders in terms of votes, and the fourth shall be the Chair of the Board of Directors.
The Nomination Committee will consist of the following persons who together represent 5,65 percent of the number of shares and votes in the Company as of September 30, 2024:
- Christer Køhler, representing Jens Henrik Jensen
- Mats Leifland, representing Vincent Saldell
- Sara Ek, representing Carl Borrebaeck and
- Peter Høngaard Andersen in his capacity as Chair of the Board of Directors
Jeff Borcherding, the CEO of Immunovia AB, in his capacity as one of the company's largest shareholders, declined the opportunity to appoint a representative to the Nomination Committee in order to ensure the independence of the committee.
The Nomination Committee will prepare proposals for shareholder approval at the 2025 Annual General Meeting (AGM). In particular, the Nomination Committee will nominate candidates for the Immunovia Board of Directors, ensuring the board has the appropriate skills and experience to support the company's success in 2025. The Nomination Committee will also recommend appropriate compensation to be offered to the Board of Directors based on proper benchmarks. Further, the Committee will recommend the election and compensation of the company's auditors.
"It's a pleasure to have the nomination committee in place to start the work leading up to the AGM 2025. It is of vital importance that the competencies of Immunovia's board members reflect the transition of the company's focus from research and development to commercialization in the US," says Peter Høngaard Andersen, Chair of the Board of Directors.
The Nomination Committee's conclusions and proposals will be presented in the notice to the Annual General Meeting 2025, which will be held on May 14, 2025. Further information on the principles and duties of the Nomination Committee can be found at https://investor.immunovia.com/governance/nomination-committee/
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
The information was submitted for publication, through the agency of the contact persons set out above, at 13:45 CET on January 8, 2025.
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-ab--publ--presents-nomination-committee,c4088998
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-ab-publ-presents-nomination-committee-302345774.html
SOURCE Immunovia AB
FAQ
When is Immunovia's (IMMNOV) 2025 Annual General Meeting scheduled?
What percentage of shares does Immunovia's (IMMNOV) new Nomination Committee represent?
How many high-risk individuals could benefit from Immunovia's (IMMNOV) pancreatic cancer testing in the USA?
What is the main business transition Immunovia (IMMNOV) is currently undertaking?
